FLT-PET / MRI Brain Mets

Launched by UNIVERSITY HEALTH NETWORK, TORONTO · Jan 24, 2020

Keywords

ClinConnect Summary

This clinical trial is studying a new way to differentiate between two complications that can occur after treatment for brain metastases, which are cancer tumors that have spread to the brain. After a treatment called stereotactic radiosurgery (SRS), some patients may experience radionecrosis (RN), where healthy brain tissue is damaged, or tumor progression, where the cancer continues to grow. Both conditions can cause similar symptoms and look alike on standard imaging tests, making it hard for doctors to know which one is affecting a patient. This trial aims to see if a special imaging technique called hybrid FLT-PET/MRI can help doctors tell the difference without needing surgery.

To be eligible for this study, participants must be at least 18 years old, have been treated with SRS for brain metastases before, and have new brain lesions that may be RN or tumor progression. They should also be scheduled for surgery on the affected area. Participants will undergo the hybrid imaging procedure before their surgery, which will help provide important information for their diagnosis and treatment plan. It's worth noting that this trial is currently recruiting patients, and individuals who meet the criteria can contribute to advancing our understanding of these conditions.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • 1. 18 years or older
• • 2. Previously treated with SRS for BrM
• • 3. New intracranial lesion with clinical and radiographic findings suspicious for either RN or tumour progression
• • 4. May be planned surgical resection of the lesion in question. The determination that the lesion is appropriate for and may require surgical resection will be made by the multi-disciplinary brain metastasis team. Surgery is preferred but not required. If a patient is planned for surgery, the date does not need to be established and the patient does not need to have consented in order to be eligible for this study, however the imaging procedure will need to occur prior to the date of surgery.
• • 5. A negative serum pregnancy test within the two-week interval immediately prior to PET-MRI imaging for women of child-bearing age
• • 6. Ability to provide written informed concern to participate in the study
• Exclusion Criteria:
• • 1. Previous radiotherapy to the intended treatment volume
• • 2. Active malignancy other than sarcoma
• • 3. Inability to remain supine for at least 60 minutes
• • 4. Pregnancy or breast feeding
• • 5. Age \<18 years
• • 6. Failure to provide written informed consent
• • 7. Contraindication for MRI as per current institutional guidelines